Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nexstim Oyj's Enterprise Value is €75.97 Mil.
Nexstim Oyj's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €0.56 Mil. Therefore, Nexstim Oyj's EV-to-EBIT ratio for today is 134.94.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Nexstim Oyj's Enterprise Value is €75.97 Mil.
Nexstim Oyj's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1.73 Mil. Therefore, Nexstim Oyj's EV-to-EBITDA ratio for today is 43.86.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Nexstim Oyj's Enterprise Value is €75.97 Mil.
Nexstim Oyj's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €11.69 Mil. Therefore, Nexstim Oyj's EV-to-Revenue ratio for today is 6.50.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Nexstim Oyj's Enterprise Value is €75.97 Mil.
Nexstim Oyj's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.31 Mil. Therefore, Nexstim Oyj's EV-to-FCF ratio for today is -247.46.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Nexstim Oyj (OHEL:NXTMH) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Nexstim Oyj's current Enterprise Value is €75.97 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €0.56 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Nexstim Oyj's current Enterprise Value is €75.97 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1.73 Mil.
Nexstim Oyj's current Enterprise Value is €75.97 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €11.69 Mil.
Nexstim Oyj's current Enterprise Value is €75.97 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €1.20 Mil.
Nexstim Oyj's current Enterprise Value is €75.97 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexstim Oyj Enterprise Value Related Terms
Nexstim Oyj Enterprise Value Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OHEL:NXTMH vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Nexstim Oyj's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Nexstim Oyj's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexstim Oyj (OHEL:NXTMH) has a Enterprise Value of €75.97 Mil as of Sep. 07, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Nexstim Oyj and its competitors.
Is Nexstim Oyj's Enterprise Value too high?
Nexstim Oyj's current Enterprise Value is €75.97 Mil. Overall, Nexstim Oyj has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's Enterprise Value compare to ABT and SYK?
Nexstim Oyj's Enterprise Value of €75.97 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Nexstim Oyj and its competitors. Nexstim Oyj's current Enterprise Value is €75.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (OHEL:NXTMH) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.38, compared to a current price of €10.80 — trading 15.1% above its estimated fair value. The current Enterprise Value is €75.97 Mil. Nexstim Oyj's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Nexstim Oyj (OHEL:NXTMH), the current Enterprise Value is €75.97 Mil as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (OHEL:NXTMH) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €10.80 is trading 15.1% above its estimated GF Value™ of €9.38.
GuruFocus considers Nexstim Oyj to be Modestly Overvalued.
Key valuation signals for OHEL:NXTMH:
Enterprise Value: €75.97 Mil
GF Value™: €9.38 vs. price of €10.80 (15.1% above fair value)
No single metric tells the full story. See the OHEL:NXTMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
61GF Score
Get the complete analysis for OHEL:NXTMH
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OHEL:NXTMH has been successfully added to your 
